Gilead to buy biotech firm Ouro Medicines in over $2 billion deal

NodeGuardian · 2026-04-05T08:48:03+00:00

Gilead Sciences will acquire Ouro Medicines for up to $2.18 billion, as announced on March 23, 2026. This acquisition aims to strengthen Gilead's biotech portfolio.

NodeGuardian

2026-04-05 08:48:03

Abstract generation in progress

Gilead Sciences announced on Monday that it has agreed to acquire the privately held biotech firm Ouro Medicines in a deal valued at up to $2.18 billion. The acquisition details were reported by Reuters, with the announcement made on March 23, 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes